Hepatorenal Syndrome Treatment Market

Exponential Growth in Therapeutics Boosts Growth of Hepatorenal Syndrome Treatment Market

Improvements in the therapeutics landscape of the hepatorenal syndrome treatment market are creating new avenues in incremental opportunities for healthcare companies. Although surgical treatments dominate the hepatorenal syndrome (HRS) treatment market, analysts at Transparency Market Research (TMR) anticipate an exponential growth for therapeutics in terms of market value share. Therapeutics are projected to rise from a market value share of ~1% in 2018 to ~6% by the end of 2027, in the hepatorenal syndrome treatment market. Thus, lucrative opportunities in the therapeutics landscape are attracting the attention of healthcare companies.

Healthcare companies are developing improved formulations of therapeutic drugs that are safe and effective for HRS patients. For instance, in May 2019, Mallinckrodt - a global specialty pharmaceutical company, announced the launch of Terlipressin - an investigational agent for the treatment of type 1 hepatorenal syndrome.

Since there are no treatments approved in the U.S. and Canada for HRS-1, healthcare companies are increasing their research efforts to reach full potential in terms of the enrollment of participants. Thus, active enrollment of participants in clinical studies will help enhance the credibility of research outcomes in the hepatorenal syndrome treatment market.

Request the Coronavirus Impact Analysis on this Markets -  https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=33815

To know the scope of our report Get a Sample on Hepatorenal Syndrome Treatment Market   

Health Commissions Recommend Albumin as Cost-effective Treatment Option for Cirrhosis and HRS

Complications of cirrhosis lead to HRS and progressive kidney failure amongst patients with severe liver damage. Hence, healthcare providers prescribe albumin to cirrhotic patients with acute decompensation. Albumin is gaining increased popularity in the hepatorenal syndrome treatment market, since it serves as a cost-effective treatment option for HRS and cirrhosis. As such, there is growing demand for albumin in hospitals and ambulatory surgical centers across Germany, Italy, and Spain.

Get a glimpse of the in-depth analysis through our Report Brochure

Healthcare companies in the hepatorenal syndrome treatment market are increasing their production capabilities of albumin, since the protein serves as a low-cost and effective alternative to saline, gelatin, and no fluid treatment of large volume paracentesis (LVP). It is found that, the combination of albumin with antibiotics is clinically more effective than antibiotics alone in the hepatorenal syndrome treatment landscape. To reduce the severe complications of cirrhosis amongst HRS patients, healthcare companies in the hepatorenal syndrome treatment market are increasing awareness about the combination therapy of albumin with vasoconstrictors.

Albumin is being increasingly used in combination with other drugs such as terlipressin. This trend is gaining increased popularity due to its low medical complication costs. Due to reduced rates of renal impairment and reduced mortality rates, health commissions across various countries are recommending the prescription of albumin to treat serious conditions of HRS.

Economic Evaluation Helps Companies Analyze Cost Difference for HRS Treatment Options

HRS is characterized by renal failure in patients suffering from advanced chronic liver disease (CLD). This disease condition has led to increased hospitalizations in the U.S. As such, the U.S. currently accounts for the highest revenue amongst all regions in the hepatorenal syndrome treatment market, with a value recorded at ~US$ 5 billion in 2018. Therefore, companies in the hepatorenal syndrome treatment market are increasing their efforts to introduce advanced treatment options for HRS patients in the U.S. However, it is found that, there is a growing need for cost-efficient treatment alternatives for the diagnosis of HRS in the U.S. Costly HRS treatments have created the problem of economic burden amongst patients. This has adversely affected the credibility of outcomes, as patients lack access to cost-efficient and effective treatment options.

Hence, companies in the hepatorenal syndrome treatment market are carrying out extensive research to analyze the number of hospitals that offer treatments at a higher cost. This is particularly compared with hospitals in the developing countries of Asia Pacific. For instance, it has been found that, the cost of treatment for HRS is less expensive in India as compared to the economic evaluation of treatment offered in Brazil. Companies in the hepatorenal syndrome treatment market are increasing research & development to devise strategies that reduce the economic burden on patients, and are increasing the availability of effective treatment options at U.S. hospitals.

About This Author

monali Joined: April 13th, 2018